#news

Thalassemia Foundation of Canada to Host its National Thalassemia Conference on October 23-24
Νέα

Thalassemia Foundation of Canada to Host its National Thalassemia Conference on October 23-24

The Thalassemia Foundation of Canada, a long-time member of TIF, will be holding its 2-day Virtual National Conference on Thalassaemia this weekend, October 23-24, at 12:00-16:00 EDT. The Conference aims at…
TIF Takes Active Part In The 71st Session of the WHO Regional Committee for Europe
Νέα

TIF Takes Active Part In The 71st Session of the WHO Regional Committee for Europe

TIF has participated in the 71st session of the WHO Regional Committee for Europe between 13–15 September 2021, which gathered six hundred high-level delegates, including over 30 Health Ministers from…
TIF Participates in EMA’s Annual Training Day 2020
Νέα

TIF Participates in EMA’s Annual Training Day 2020

TIF has participated in the Annual Training Day of the European Medicines Agency (EMA), held on 23 October 2020. TIF participants, Ms Lily Cannon (TIF Operations Manager) and Ms Eleni…
TIF Webinar Fridays Are Back With A New Session on “Heart Disease In Thalassaemia”
Νέα

TIF Webinar Fridays Are Back With A New Session on “Heart Disease In Thalassaemia”

This Friday, 23 October 2020, at 15:00 EEST/13:00 BST, get ready to join Prof. Malcolm Walker and Dr. Dimitris Farmakis in our webinar on ”Heart Disease In Thalassaemia” for Patients/Parents,…
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in β-Thalassaemia
Κλινικά Νέα

Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in β-Thalassaemia

Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin,  announced dosing of the first patient…
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Κλινικά Νέα

Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness

Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles
Νέα

Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles

As public healthcare resources are redirected to halt the spread of coronavirus, victims of other life-threatening diseases pay the ultimate price. This recent news story, published by The Telegraph, depicts…
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Κλινικά Νέα

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics, Inc.  a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
Back to top button